Pierce Christopher 4
4 · Prelude Therapeutics Inc · Filed Apr 15, 2021
Insider Transaction Report
Form 4
Pierce Christopher
EVP and Chief of Business Oper
Transactions
- Sale
Common Stock
2021-04-08$40.00/sh−200$8,000→ 3,750 total - Award
Common Stock
2021-04-08$1.89/sh+200$378→ 3,950 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-08−200→ 7,618 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (200 underlying)
Footnotes (2)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The stock option is fully vested.